BLAINJECTIONINJECTABLE
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FILKRI (filgrastim-laha) by Accord Biopharma is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. First approved in 2026.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILKRI is a granulocyte colony-stimulating factor (G-CSF) analog developed by Accord Biopharma that stimulates neutrophil proliferation and differentiation in the bone marrow. It is indicated for patients requiring neutrophil support, typically those undergoing chemotherapy or experiencing neutropenia. The drug works by binding to G-CSF receptors on hematopoietic cells to enhance neutrophil production and function.
Launch
Recently approved biosimilar entering a mature, competitive market; expect focused launch team with emphasis on access and payer relationships.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FILKRI positions you in a high-stakes, cost-driven market segment where payer negotiation, supply chain efficiency, and formulary placement are critical success factors. The role emphasizes commercial acumen and real-world evidence generation over clinical innovation.
Worked on FILKRI at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.